Liver Transplantation Prevents Progressive Neurological Impairment in Argininemia by Santos-Silva, E. et al.
CASE REPORT
Liver Transplantation Prevents Progressive Neurological
Impairment in Argininemia
E. Santos Silva • M.L. Cardoso • L. Vilarinho •
M. Medina • C. Barbot • E. Martins
Received: 07 December 2012 /Revised: 08 February 2013 /Accepted: 08 February 2013
# SSIEM and Springer-Verlag Berlin Heidelberg 2013
Abstract Argininemia is a rare hereditary disease due to a
deficiency of hepatic arginase, which is the last enzyme of
the urea cycle and hydrolyzes arginine to ornithine and urea.
The onset of the disease is usually in childhood, and clinical
manifestations include progressive spastic paraparesis and
mental retardation. Liver involvement is less frequent and
usually not as severe as observed in other UCDs. For this
reason, and because usually there is a major neurological
disease at diagnosis, patients with argininemia are rarely
considered as candidates for OLT despite its capacity to
replace the deficient enzyme by an active one. We report on
long-term follow-up of two patients with argininemia.
Patient 1 was diagnosed by the age of 20 months and
despite appropriate conventional treatment progressed to
spastic paraparesis with marked limp. OLTwas performed at
10 years of age with normalization of plasmatic arginine
levels and guanidino compounds. Ten years post-OLT,
under free diet, there is no progression of neurological
lesions. The second patient (previously reported by our
group) was diagnosed at 2 months of age, during a neonatal
cholestasis workup study. OLT was performed at the age of
7 years, due to liver cirrhosis with portal hypertension, in the
absence of neurological lesions and an almost-normal brain
MRI. After OLT, under free diet, there was normalization of
plasmatic arginine levels and guanidino compounds. Twelve
years post-OLT, she presents a normal neurological exami-
nation. We conclude that OLT prevents progressive neuro-
logical impairment in argininemia and should be considered
when appropriate conventional treatment fails.
Abbreviations
CSF Cerebrospinal fluid
MRI Magnetic resonance imaging
OLT Orthotopic liver transplantation
UCDs Urea cycle disorders
Introduction
Argininemia (MIM #207800) is a rare inborn error of urea
cycle, due to arginase A1 deficiency. This enzyme is
codified by ARG1 gene and is also known as hepatic
arginase because it is responsible for 98% of arginase
activity in the liver. The clinical symptoms of argininemia
become apparent in early childhood, usually between 2 and
4 years of age. They include progressive spastic paraparesis
(with marked degree of spasticity of the four extremities)
and severe mental deterioration, which are characteristic of
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this disease (and are not observed in other UCDs)
(Brusilow and Horwich 2005; Scaglia and Lee 2006). The
neurological symptoms referred to here cannot be explained
merely as a consequence of arginine levels and hyper-
ammoniemia (which is observed intermittently), since
neurological impairment sometimes progresses despite
good compliance with treatment (presenting stable arginine
and ammonia plasmatic levels). So it was suspected that
other factors, such as the presence of guanidino com-
pounds, might be implicated in the neurological impairment
(Mizutani et al. 1987), since the endogenous production of
these substances may remain significant even when
arginine is normalized (Marescau et al. 1990).
In the past, we demonstrated that OLT can normalize
arginine, ammonia, and guanidino compounds levels in
patients with argininemia, allowing them to follow a free
diet for life (Santos Silva et al. 2001). Nevertheless, it
remains to be clarified if in patients with already existing
neurological lesions, OTL can prevent its progression,
and in the ones who have not yet developed such
symptoms, whether OLT will be able to prevent them in
the long term.
Here, we report on two patients with argininemia, with
more than 10 years follow-up after OLT, which support the
evidence that this therapeutic strategy can prevent long-
term development and progression of neurological
impairment in patients with such an inborn error of
metabolism.
Material and Methods
Amino acids profile was determined by liquid ion-exchange
chromatography.
Guanidino compounds in plasma and urine were
determined by high-performance liquid chromatography.
Case Reports
Case 1 – The patient is the first daughter of a non-
consanguineous couple with irrelevant family history.
Pregnancy and delivery were unremarkable. Birth weight
was 4,100 g and height 51 cm. No neonatal jaundice was
reported. She was overweight since the second year of life,
and the motor milestones and cognitive development were
normal.
She was diagnosed with infectious mononucleosis by 20
months of age, followed by persistent rise of transaminases
and asymptomatic coagulation abnormalities. Biochemical
data included total bilirubin 12 μmol/L, conjugated biliru-
bin 2.5 μmol/L, AST 170 UI/L (n<56), ALT 200 UI/L
(n<39), GGT 10 UI/L (n<45), total cholesterol 4.5 mmol/L
(n:3.4–6.0), thromboplastin time 46.6 s (n<35s), and
prothrombin time 31 s (n<12s). Amino acids profile
showed an elevated arginine concentration (481 μmol/l,
n<140). Blood ammonia and urinary orotic acid were both
within the normal range. Argininemia diagnosis was
confirmed by the absence of arginase A1 activity in red
blood cells and by molecular analysis of ARG1 gene
(homozygous for R21X mutation). Other diagnoses have
been excluded by appropriate testing, namely, alpha-1-
antitrypsin deficiency, hepatitis B and C, autoimmune
hepatitis, Wilson’s disease, myopathy, and other amino-
acidopathies. After diagnosis, she started immediately on a
low-protein and arginine-restricted diet and oral sodium
benzoate 300 mg/kg/day.
Outcome was spastic paraparesis with marked limp, despite
good treatment compliance and lowering of plasmatic arginine
levels (200–300 μmol/L). She benefited from physiotherapy
and Vulpius surgery at 7 years of age. Meanwhile brain MRI,
performed 1 year later, showed increased T2 signal intensity
within the peritrigonal white matter (Fig. 1a) and increased T2
signal intensity within the semioval center, more prominent in
the left hemisphere (Fig. 1b).
School performance was satisfactory (Wechsler scale
GIQ – 97), growth was appropriate (height p50), but
overweight was always an unsolved problem. She had
raised transaminases, mild coagulation abnormalities, and
liver steatosis (ultrasound). By the age of 8 years, she
started oral phenylbutyrate 250 mg/kg/day, without much
success in decreasing more effectively the levels of blood
arginine. By this time, guanidino compounds in plasma and
urine were markedly elevated (Fig. 2).
As spastic paraparesis worsened, it was proposed to the
family to perform a liver transplant and thus cure the
hepatic enzymatic deficiency. OLT was performed on the
patient when she was 10 years old (at the Liver Transplan-
tation Center of Coimbra – Portugal) with complete
normalization of plasmatic arginine levels 24 h after OLT,
and since then she has remained on an unrestricted diet.
After OLT, plasmatic and urinary guanidine compounds
also became normal (Fig. 2) and progression of the
neurological disease stopped immediately. Ten years later,
there has been no progression of neurological features or
new MRI abnormalities (Fig. 1c and d).
Case 2 – This patient was previously reported upon
(Braga et al. 1997; Santos Silva et al. 2001; Martins et al.
2011). Diagnosis of argininemia was made by 2 months
of age during the workup of a neonatal cholestasis
(plasma arginine 1,756 μmol/L, n: 22–88), and was
confirmed by the absence of arginase A1 activity in blood
red cells and by molecular analysis of ARG1 gene
(homozygous for R21X mutation) (Cardoso et al. 1999).
She was put on a low-protein and arginine-restricted diet,
and oral sodium benzoate. The outcome was liver cirr-
hosis with portal hypertension, marked hypercholesterolemia
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(18.0 mmol/L, N:3.4–6.0), xanthomatosis, and pruritus.
Despite an extensive investigation, no other cause was
established for this kind of liver involvement. By the age of
7 years, she had terminal liver cirrhosis, growth develop-
ment delay (P<3), General Quotient Development ¼ 80
(Griffiths method), and normal neurological features.
Despite suitable dietary compliance, arginine plasmatic
levels were around 300 μmol/l and guanidino compounds
were markedly raised (Fig. 2). Brain MRI studies showed
increased T1 signal intensity in the pallidum nucleus and no
T2 signal abnormalities in the peritrigonal white matter. At
this point, she underwent OLT at the Liver Transplantation
Fig. 1 Brain MRI studies in Patient 1. Before OLT we detected
(a) an increased T2 signal intensity within the peritrigonal white
matter (black circle and arrow) and (b) increased T2 signal intensity
within the semioval center, more prominent in the left hemisphere.
Later, 15 months post-OLT we found (c) an increased T2 signal
intensity within the peritrigonal white matter, and (d) within the
semioval center (more prominent in the left hemisphere), but less
severe than before OLT (red arrows)
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Center of Coimbra – Portugal. We observed a slight and
transient hyperammoniemia with complete normalization
of arginine and ammonia blood levels 24 h after OLT.
When the patient started a free diet, blood arginine and
ammonia levels remained normal and those of guanidino
compounds normalized (Fig. 2). Twelve years after OLT,
we note that neurological features, plasmatic arginine
levels, and guanidino compounds remain normal. She has
Fig. 2 Plasmatic and urinary levels of guanidino compounds in
patients with argininemia. Patient 1 first control post-OLT at * 20
months and later ** at 8 years post-OLT. Patient 2 first control
post-OLT at * 26 months and later ** at 4.5 years post-OLT.
a-KVA a-keto-d guanidinovaleric acid, CR creatine, GAA guanidino-
acetic acid, aAA a-N-acetylarginine, ARGA argininic acid, Creat
creatinine, YGBA g-guanidinobutyric acid, Arg arginine, HARG
homoarginine, GND guanidine
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a healthy and unaffected sibling, born July 2000, after
molecular prenatal diagnosis.
Discussion
In several metabolic diseases, liver transplant, despite
correcting the hepatic enzymatic deficiency, fails in stopping
long-term consequences of the disease. As no data is
available on the long-term surveillance of patients submitted
to liver transplant for argininemia, this report is imperative.
Argininemia treatments that successfully lower arginine
and guanidino compounds levels should prevent neurologi-
cal symptoms, but although arginine plasmatic levels may
normalize under conventional treatment, the arginine’s
catabolites can remain elevated (Marescau et al. 1990),
and some of these guanidino compounds are neurotoxic
(De Deyn et al. 2009; Hiramatzu, 2003). In both of our
patients, arginine concentration decreased significantly
under conventional treatment (but never normalized), and
guanidine compounds were markedly elevated in plasma
and urine. However, after OLT all these parameters
normalized completely (Fig.2).
It would have been very interesting to evaluate the
guanidino compounds also in CSF, however, that was not
possible because Patient 1 never cooperated, and Patient
2 had terminal liver disease, with portal hypertension,
thrombocytopenia, and coagulation abnormalities, which
made the procedure unwise.
Patient 1 had a relatively early diagnosis (<2 years
old) compared with the cohort of Portuguese symp-
tomatic patients (12 patients, age of diagnosis > 3
years in the majority of cases). At diagnosis, she had
subclinical liver disease (occasional finding) and was
neurologically asymptomatic. Furthermore, she started
conventional treatment immediately, with good compli-
ance, and success in lowering the plasmatic levels of
arginine. Despite everything, she developed progressive
paraparesis and marked limp. Patient 2 had an
uncommon form of presentation of argininemia (Braga
et al. 1997; Martins et al. 2011) and benefited from an
unusual early diagnosis and treatment (by 2 months of
age). As in Patient 1, arginine plasmatic levels decreased
significantly but never got completely normal. This
patient never developed neurological impairment. Both
patients had markedly elevated guanidino compounds
pre-OLT. Perhaps the explanation for the different
neurological outcome in these two patients is that vast
brain growth with organizational changes takes place
during the first two postnatal years (Knickmeyer et al.
2008). Thus, any toxic factor acting on the brain during
this period of time will be more harmful and leave the
worst possible sequels. Patient 1 was much more exposed
to neurotoxicity in this crucial period for brain develop-
ment than Patient 2.
When Patient 1 started to show signs of neurological
impairment, we already had the experience of following
other patients, under conventional treatment, with inexo-
rable progression to spastic tetraparesis and severe mental
retardation (unpublished data). But this time, we also had
the experience of the first OLT performed in a patient with
argininemia (Santos Silva et al. 2001). The encouraging
result of OLT in Patient 2 prompted us to transplant
Patient 1, in order to stop progression of neurological
impairment. This aim was completely achieved. In Patient
1, progression of neurological disease stopped immedi-
ately, and there was even some regression in MRI features
(Fig.1). This effect has been sustained 10 years after OLT.
Patient 2 remains free of neurological disease 12 years
post-OLT.
These two clinical observations also suggest that
although the highest aggression for the brain may occur
during the first 2 years of life, it may continue while no
complete normalization of biochemical parameters is
achieved, mainly of guanidino compounds levels. They
also show that once normalization happens, the progression
of the neurological disease stops. Based on such observa-
tions, it is recommended that patients with argininemia
should be carefully monitored clinically (and biochemi-
cally) for early detection of the development of neurologi-
cal symptoms.
Argininemia is the second most common urea cycle
disease in Portugal, after ornithine transcarbamylase
deficiency (1/215,000 live newborns) (Martins et al.
2011). Since 2004, it has been included in the Portuguese
expanded newborn screening (3–6 day of life, arginine
level in dried blood spot cutoff ¼ 37 μM). If arginine is
above the cutoff level, a second blood sample is requested.
If the second blood analysis shows arginine plasmatic
level > 140 μmol/L, the neonate is called for full
assessment at a reference center. Based on this approach,
we have, until now, diagnosed four cases of argininemia in
newborns (1/181,550 live newborns) (Personal communi-
cation, E. Martins 2011), allowing the affected patients to
start conventional treatment during the first month of life
(median age 16 days), and thus protecting their brains
during infancy and childhood from exposure to high
amounts of neurotoxic compounds. The follow-up of such
patients will further help to clarify the long-term outcome
of the disease in ideally treated patients. Meanwhile, we
know that OLT is able to prevent progressive neurological
impairment in patients with argininemia, when appropriate
conventional treatment fails, and should be offered to these
patients before severe neurological impairment occurs.
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Concise Sentence Take-Home Message
OLT prevents progressive neurological impairment in
argininemia and should be considered when appropriate
conventional treatment fails.
Reference to Electronic Databases
Urea cycle disorders, argininemia, liver transplantation,
neurological impairment.
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